



Recent Advances in Protein-Drug Conjugates: From Bioanalytical, Drug Metabolism to Pharmacokinetics

Guest Editor:

Prof. Dr. Young G. Shin

College of Pharmacy and
Institute of Drug Research and
Development, Chungnam
National University, Daejeon,
Republic of Korea

Deadline for manuscript
submissions:

closed (15 March 2024)

Message from the Guest Editor

Protein–drug conjugates such as antibody–drug conjugates (ADC) have recently received significant attention due to their dramatic clinical efficacies with acceptable toxicity profiles, particularly as novel anticancer drugs. This approach comprises a protein (i.e., monoclonal antibody) conjugated to the cytotoxic payload via a chemical linker directed toward a target antigen expressed on the cancer cell surface, reducing systemic exposure and, therefore, toxicity. Thus, ADC is one of the most popular platforms but also requires a good balance among various components such as monoclonal antibody, linker, and payload from drug metabolism and pharmacokinetic perspectives. Albumin–drug conjugates (ALDCs) are another good novel platform of choice due to favorable distribution to the tumor as well as a long half-life. ALDCs are also receiving increased attention from the pharmaceutical industry as an alternative approach to overcome various cancers. In addition to protein or linker sides, new payloads are also recently introduced, such as immuno-modulators, molecular glues, and PROTACs for conjugation.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical
Biology and Phytochemistry,
University of Münster,
Corrensstrasse 48, D-48149
Münster, Germany

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Reaxys](#), [CaPlus / SciFinder](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q2 (Chemistry, Multidisciplinary) / CiteScore - Q1 (Chemistry (miscellaneous))

Contact Us

Molecules Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/molecules
molecules@mdpi.com
[X@Molecules_MDPI](https://twitter.com/Molecules_MDPI)